Patents by Inventor Scott Dusan Pegan

Scott Dusan Pegan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
    Patent number: 9795665
    Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 24, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Crimean-Congo hemorrhagic fever virus vaccine
    Patent number: 9474796
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 25, 2016
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Colorado Seminary, which owns and operates the University of Denver
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
    Patent number: 9394254
    Abstract: This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: July 19, 2016
    Assignee: The University of Denver and Regis University
    Inventors: Scott Dusan Pegan, Kateri Ahrendt, Glenn C. Capodagli, Bryan Cowen
  • ATTENUATED LIVE VACCINE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS AND ERVE VIRUS
    Publication number: 20150306202
    Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.
    Type: Application
    Filed: August 13, 2013
    Publication date: October 29, 2015
    Inventors: Eric BERGERON, Scott Dusan PEGAN, Stuart T. NICHOL, Michelle Kay DEATON
  • Antibiotic and Anti-Parasitic Agents that Modulate Class II Fructose 1, 6-Bisphosphate Aldolase
    Publication number: 20140336221
    Abstract: This invention provides a family of compounds that inhibit Class II fructose 1,6-bisphosphate aldolase (FBA), which is implicated in the pathogenic activity of a broad range of bacterial and parasitic agents. The compounds were identified by empirical testing, and provide a basis for further derivatization and optimization of 8-hydroxyquinoline-2-carboxylic acid and related compounds. Crystal structure shows that the compounds don't bind directly to the catalytic site of the enzyme, and so are not defined simply as substrate analogs. Instead, they create a pocket by induced fit, resulting a powerful and specific inhibitory effect on FBA activity.
    Type: Application
    Filed: May 8, 2014
    Publication date: November 13, 2014
    Applicants: Colorado Seminary, Which Owns and Operates The University Of Denver, Regis University
    Inventors: Scott Dusan Pegan, Kateri Ahrendt, Glenn C. Capodagli, Bryan Cowen
  • Crimean-Congo Hemorrhagic Fever Virus Vaccine
    Publication number: 20140050761
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 20, 2014
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton